Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM): Final analysis of transplant-ineligible (TIE) pts in the phase 3 CEPHEUS study.
Saad Z. Usmani, Thierry Facon, Vania Hungria, Nizar Jacques J. Bahlis et autres
us, fr, br, ca, cz, es, gb, il, jp, pl, tr, nl (code pays fourni par la source)